Loading…
Loading…
Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript
SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi syndrome (PWS) and metabolic diseases, today reported exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE) trial. As previously announced, Aardvark unblinded the data accumulated across both the HERO trial and OLE trial to assess the totality of available efficacy and safety data to inform the path forward for ARD-101.
Envestnet Asset Management Inc. raised its holdings in Global X Video Games and Esports ETF (NASDAQ: HERO) by 306.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 141,909 shares of the company's stock after purchasing an additional 106,976 shares during the
AARD DEADLINE NOTICE: Faruqi and Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026PR NewswireNEW YORK,
AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class ActionPR NewswireSAN FRANCISCO,
Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadli
Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 De